Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Savara Inc.
Potential Milestone Year Ahead For Korean NASH Contenders
Scrip takes a look at key recent drug development activities in the NASH area by Korean firms, which are now pursuing the global development of their candidates as they look to leverage innovation to expand internationally.
Recent US FDA Breakthrough Therapy Designations, From Mass Market Vaccines To Rare Diseases
Merck’s latest pneumococcal vaccine and Pfizer’s RSV vaccine notched new BTDs, along with Zambon’s inhaled antibiotic for non-CF bronchiectasis, Acer’s vascular Ehlers-Danlos syndrome drug and Dizal’s targeted lung cancer candidate.
Finance Watch: Biopharma IPOs Regain Momentum With Slate Of New Offerings
Public Company Edition: Instil Bio, Connect Biopharma, Finch Therapeutics, Gain Therapeutics and four heath care-focused SPACs launched initial public offerings; Endo raised $1.3bn via note sale; and Rubius Therapeutics, Solid Biosciences and others priced follow-on offerings.
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
- Drug Delivery
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Serendex ApS, Mast Therapeutics, Inc.
- SD Pharmaceuticals Inc
- Savara ApS
- Synthrx, Inc.
- Aires Pharmaceuticals, Inc.
- Savara Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.